Santé Ventures has closed its fifth fund with $330 million in committed capital, surpassing a $300 million target and marking the firm’s largest fund to date. The early-stage healthcare and life sciences investor said Fund V will continue backing biotechnology, medical technology, and digitally enabled healthcare companies aimed at significant unmet medical needs, supported by what it described as a broader and more diversified limited partner base.
Founded in 2006, the firm said it has built a track record of leading early-stage investments that have resulted in notable exits, including Laminar, Farapulse, AbVitro, and Explorys, among others. Santé said Fund V will follow its existing approach, centered on thematic investing, rigorous scientific diligence, and hands-on company creation, with a particular focus on areas where care delivery is complex, capital is inefficiently used, or models are outdated.
Alongside the fund’s close, Santé announced the promotions of Dennis McWilliams and Omar Khalil to Managing Directors, noting that both have played key roles in shaping investment strategy and supporting portfolio development. The firm said it manages more than $1 billion in capital and operates from offices in Austin and Boston.
KEY QUOTES:
“Fund V represents a continuation of our mission to partner with exceptional entrepreneurs driving breakthrough science and transformative healthcare solutions. We are deeply grateful for the support of our limited partners, who share our conviction that innovation at the intersection of science, medicine, and technology can fundamentally improve patient outcomes.”
“Dennis and Omar have been instrumental to our success and embody the collaborative, science-driven approach that defines Santé. Their leadership meaningfully strengthens our ability to partner with world-class founders and build companies that make a lasting impact on healthcare.”
Kevin Lalande, Founding Managing Director and Chief Investment Officer, Santé Ventures
